Eyal C. Attar Sells 10,334 Shares of Vor Biopharma Inc. (NYSE:VOR) Stock

Vor Biopharma Inc. (NYSE:VOR) insider Eyal C. Attar sold 10,334 shares of the business’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $1.25, for a total value of $12,917.50. Following the transaction, the insider now directly owns 81,439 shares of the company’s stock, valued at approximately $101,798.75. This represents a 11.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Vor Biopharma Stock Performance

VOR opened at $1.11 on Thursday. Vor Biopharma Inc. has a one year low of $0.63 and a one year high of $3.14. The stock has a market capitalization of $76.23 million, a P/E ratio of -0.67 and a beta of -0.37. The business’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $0.89.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). On average, equities research analysts forecast that Vor Biopharma Inc. will post -1.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC grew its position in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares during the last quarter. Hsbc Holdings PLC grew its holdings in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vor Biopharma in the 2nd quarter valued at about $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vor Biopharma in the 2nd quarter valued at about $63,000. Finally, Exchange Traded Concepts LLC raised its stake in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares during the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

VOR has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird dropped their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Monday, December 9th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma has an average rating of “Buy” and a consensus target price of $11.36.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.